$3.86
Live
1.04%
Downside
Day's Volatility :4.98%
Upside
3.98%
44.82%
Downside
52 Weeks Volatility :72.45%
Upside
50.06%
Period | Puma Biotechnology, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -21.51% | 6.5% | 0.0% |
6 Months | -19.1% | 7.1% | 0.0% |
1 Year | 12.25% | 9.8% | 0.0% |
3 Years | -49.23% | 14.2% | -20.2% |
Market Capitalization | 179.9M |
Book Value | $1.06 |
Earnings Per Share (EPS) | 0.32 |
PE Ratio | 11.66 |
PEG Ratio | 0.03 |
Wall Street Target Price | 4.33 |
Profit Margin | 6.78% |
Operating Margin TTM | -5.25% |
Return On Assets TTM | 8.1% |
Return On Equity TTM | 40.02% |
Revenue TTM | 226.6M |
Revenue Per Share TTM | 4.77 |
Quarterly Revenue Growth YOY | -17.1% |
Gross Profit TTM | 172.9M |
EBITDA | 38.1M |
Diluted Eps TTM | 0.32 |
Quarterly Earnings Growth YOY | -0.78 |
EPS Estimate Current Year | 0.24 |
EPS Estimate Next Year | 0.24 |
EPS Estimate Current Quarter | -0.22 |
EPS Estimate Next Quarter | 0.03 |
What analysts predicted
Upside of 12.18%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 251.0M | ↑ 806.14% |
Net Income | -113.6M | ↓ 61.1% |
Net Profit Margin | -45.26% | ↑ 1008.89% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 272.3M | ↑ 8.49% |
Net Income | -82.7M | ↓ 27.18% |
Net Profit Margin | -30.38% | ↑ 14.88% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 225.1M | ↓ 17.33% |
Net Income | -60.0M | ↓ 27.47% |
Net Profit Margin | -26.65% | ↑ 3.73% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 253.2M | ↑ 12.48% |
Net Income | -29.1M | ↓ 51.5% |
Net Profit Margin | -11.49% | ↑ 15.16% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 228.0M | ↓ 9.95% |
Net Income | 912.0K | ↓ 103.13% |
Net Profit Margin | 0.4% | ↑ 11.89% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 235.6M | ↑ 3.35% |
Net Income | 21.6M | ↑ 2267.43% |
Net Profit Margin | 9.16% | ↑ 8.76% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 65.7M | ↑ 15.06% |
Net Income | -5.6M | ↑ 1455.56% |
Net Profit Margin | -8.52% | ↓ 7.89% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 52.8M | ↓ 19.67% |
Net Income | 1.4M | ↓ 125.02% |
Net Profit Margin | 2.65% | ↑ 11.17% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 54.6M | ↑ 3.4% |
Net Income | 2.1M | ↑ 51.75% |
Net Profit Margin | 3.9% | ↑ 1.25% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 56.1M | ↑ 2.84% |
Net Income | 5.8M | ↑ 172.62% |
Net Profit Margin | 10.33% | ↑ 6.43% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 72.2M | ↑ 28.62% |
Net Income | 12.3M | ↑ 111.66% |
Net Profit Margin | 17.0% | ↑ 6.67% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 43.8M | ↓ 39.36% |
Net Income | -4.8M | ↓ 139.25% |
Net Profit Margin | -11.0% | ↓ 28.0% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 259.1M | ↑ 56.55% |
Total Liabilities | 224.8M | ↑ 100.33% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 234.9M | ↓ 9.35% |
Total Liabilities | 217.4M | ↓ 3.28% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 244.2M | ↑ 3.97% |
Total Liabilities | 250.2M | ↑ 15.05% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 226.6M | ↓ 7.22% |
Total Liabilities | 229.0M | ↓ 8.45% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 222.1M | ↓ 2.0% |
Total Liabilities | 200.5M | ↓ 12.48% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 230.5M | ↑ 3.81% |
Total Liabilities | 177.1M | ↓ 11.66% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 222.1M | ↑ 11.72% |
Total Liabilities | 200.5M | ↑ 13.5% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 196.3M | ↓ 11.62% |
Total Liabilities | 170.4M | ↓ 14.99% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 200.5M | ↑ 2.16% |
Total Liabilities | 170.1M | ↓ 0.18% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 203.6M | ↑ 1.55% |
Total Liabilities | 164.9M | ↓ 3.08% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 230.5M | ↑ 13.22% |
Total Liabilities | 177.1M | ↑ 7.41% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 214.1M | ↓ 7.1% |
Total Liabilities | 163.2M | ↓ 7.86% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -24.1M | ↓ 86.03% |
Investing Cash Flow | -57.6M | ↑ 273.3% |
Financing Cash Flow | 108.4M | ↑ 44.34% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 22.4M | ↓ 192.95% |
Investing Cash Flow | 5.2M | ↓ 108.96% |
Financing Cash Flow | -67.1M | ↓ 161.9% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 800.0K | ↓ 96.43% |
Investing Cash Flow | 23.4M | ↑ 353.28% |
Financing Cash Flow | 100.0K | ↓ 100.15% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 20.7M | ↑ 2487.5% |
Investing Cash Flow | -10.9M | ↓ 146.49% |
Financing Cash Flow | -31.9M | ↓ 32000.0% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -15.8M | ↓ 176.33% |
Investing Cash Flow | 7.1M | ↓ 165.29% |
Financing Cash Flow | 12.2M | ↓ 138.24% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 7.7M | ↓ 55.48% |
Investing Cash Flow | -11.9M | ↓ 248.45% |
Financing Cash Flow | 2.4M | ↓ 4686.79% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 2.6M | ↓ 65.6% |
Investing Cash Flow | -17.5M | ↑ 46.97% |
Financing Cash Flow | 0.0 | ↓ 100.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 3.3M | ↑ 24.71% |
Investing Cash Flow | -4.7M | ↓ 73.16% |
Financing Cash Flow | 0.0 | - |
Sell
Neutral
Buy
Puma Biotechnology, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Puma Biotechnology, Inc. | 25.48% | -19.1% | 12.25% | -49.23% | -57.17% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Puma Biotechnology, Inc. | 11.66 | 11.66 | 0.03 | 0.24 | 0.4 | 0.08 | NA | 1.06 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Puma Biotechnology, Inc. | Sell | $179.9M | -57.17% | 11.66 | 6.78% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Puma Biotechnology, Inc.
Revenue is down for the last 2 quarters, 72.17M → 43.76M (in $), with an average decrease of 39.4% per quarter
Netprofit is down for the last 2 quarters, 12.26M → -4.81M (in $), with an average decrease of 139.3% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 49.3%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 235.7%
Vanguard Group Inc
Millennium Management LLC
Acadian Asset Management LLC
Renaissance Technologies Corp
Camber Capital Management LLC
BlackRock Inc
we focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.
Organization | Puma Biotechnology, Inc. |
Employees | 185 |
CEO | Mr. Alan H. Auerbach |
Industry | Health Technology |
A Spac I Acquisition Corp
$3.86
-2.03%
Keyarch Acquisition Corp
$3.86
-2.03%
Connexa Sports Technologies Inc
$3.86
-2.03%
Us Value Etf
$3.86
-2.03%
First Wave Biopharma Inc
$3.86
-2.03%
Global X Msci Next Emerging
$3.86
-2.03%
Fat Projects Acquisition Corp
$3.86
-2.03%
Capital Link Global Fintech
$3.86
-2.03%
Applied Uv Inc
$3.86
-2.03%